RedHill Biopharma (RDHL) Set to Announce Earnings on Monday

RedHill Biopharma (NASDAQ:RDHL) is set to post its quarterly earnings results before the market opens on Monday, June 24th. Analysts expect the company to announce earnings of ($0.03) per share for the quarter.

RedHill Biopharma Stock Performance

Shares of NASDAQ RDHL opened at $0.37 on Friday. The firm has a fifty day simple moving average of $0.44 and a two-hundred day simple moving average of $0.69. RedHill Biopharma has a 12 month low of $0.26 and a 12 month high of $3.28.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of RedHill Biopharma in a research note on Friday. They issued a “hold” rating for the company.

About RedHill Biopharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.